The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Abstract
CONTEXT: Neurocognitive impairment in schizophrenia is severe and is an important predictor of functional outcome. The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined. OBJECTIVE: To compare the neurocognitive effects of several second-generation antipsychotics and a first-generation antipsychotic, perphenazine. DESIGN: Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al. Ziprasidone hydrochloride was included after its approval by the Food and Drug Administration. SETTING: Fifty-seven sites participated, including academic sites and treatment mental health facilities representative of the community. PATIENTS: From a cohort of 1460 patients in the treatment study, 817 completed neurocognitive testing immediately prior to randomization and then after 2 months of treatment. MAIN OUTCOME MEASURES: The primary outcome was change in a neurocognitive composite score after 2 months of treatment. Secondary outcomes included neurocognitive composite score change at 6 months and 18 months after continued treatment and changes in neurocognitive domains. RESULTS: At 2 months, treatment resulted in small neurocognitive improvements of z = 0.13 for olanzapine (P<.002), 0.25 for perphenazine (P<.001), 0.18 for quetiapine (P<.001), 0.26 for risperidone (P<.001), and 0.12 for ziprasidone (P<.06), with no significant differences between groups. Results at 6 months were similar. After 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups. Neurocognitive improvement predicted longer time to treatment discontinuation, independently from symptom improvement, in patients treated with quetiapine or ziprasidone. CONCLUSIONS: After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition. There were no differences between any pair of agents, including the typical drug perphenazine. These results differ from the majority of previous studies, and the possible reasons are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Wechsler Intelligence Scale for Children
(2018) · The SAGE Encyclopedia of Intellectual and Developmental Disorders · doi:10.4135/9781483392271.n537 · Cited by 4,109
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Self-citationNeurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Wide Range Achievement Test-Revised
McCloskey, G. (1987) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine) · Cited by 1,375
The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry
Robbins, T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1154-7 · Cited by 1,282
Neuropsychological Function in Schizophrenia: Selective Impairment in Memory and Learning
Saykin, A. J. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810310036007 · Cited by 1,155
Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
Saykin, A. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020048005 · Cited by 1,086
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Self-citationDeterminants of Medication Compliance in Schizophrenia: Empirical and Clinical Findings
Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.637 · Cited by 957
Neuropsychology of First-Episode Schizophrenia: Initial Characterization and Clinical Correlates
Bilder, R. M., Goldman, R. S., Robinson, D., Reiter, G., Bell, L., Bates, J. A., Pappadopulos, E., Willson, D. F., Alvir, J. M. J., Woerner, M. G., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.549 · Cited by 906
Auditory Working Memory and Wisconsin Card Sorting Test Performance in Schizophrenia
Gold, J. M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830140071013 · Cited by 819
Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 693
Self-citationImpaired Attention, Genetics, and the Pathophysiology of Schizophrenia
Cornblatt, B. A., & Keilp, J. G. (1994) · Schizophrenia Bulletin · doi:10.1093/schbul/20.1.31 · Cited by 666
Stroup, T. S., McEvoy, J. P., Swartz, M. S., Byerly, M. J., Glick, I. D., Canive, J. M., McGee, M. F., Simpson, G. M., Stevens, M. C., & Lieberman, J. A. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 636
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
Self-citationWoodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605
Behavioral and Intellectual Markers for Schizophrenia in Apparently Healthy Male Adolescents
Davidson, M., Reichenberg, A., Rabinowitz, J., Weiser, M., Kaplan, Z., & Mark, M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1328 · Cited by 582
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
Keefe, R. S. E., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301072 · Cited by 472
Self-citationPurdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 469
Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.185 · Cited by 450
Castner, S. A., Williams, G. V., & Goldman-Rakic, P. S. (2000) · Science · doi:10.1126/science.287.5460.2020 · Cited by 401
Braff, D. L. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340023003 · Cited by 399
Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90043-d · Cited by 393
Harvey, P. D., Howanitz, E., Parrella, M., White, L., Davidson, M., Mohs, R. C., Hoblyn, J., & Davis, K. L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.8.1080 · Cited by 338
Fuller, R., Nopoulos, P., Arndt, S., O’Leary, D., Ho, B.-C., & Andreasen, N. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1183 · Cited by 338
Gold, J. M., Queern, C., Iannone, V. N., & Buchanan, R. W. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1944 · Cited by 325
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314
Self-citationStroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306
Self-citationRobinson, D. G., Woerner, M. G., Alvir, J. M. J., Bilder, R. M., Hinrichsen, G. A., & Lieberman, J. A. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00312-7 · Cited by 290
What Are the Right Targets for Psychopharmacology?
Hyman, S. E., & Fenton, W. S. (2003) · Science · doi:10.1126/science.1077141 · Cited by 283
Buchanan, R. W., Holstein, C., & Breier, A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90082-5 · Cited by 281
Category and letter verbal fluency across the adult lifespan: relationship to EEG theta power
BRICKMAN, A., PAUL, R., COHEN, R., WILLIAMS, L., MACGREGOR, K., JEFFERSON, A., TATE, D., GUNSTAD, J., & GORDON, E. (2005) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2004.12.006 · Cited by 221
Lieberman, J. A., Koreen, A., Chakos, M., Sheitman, B., Woerner, M. G., Alvir, J. M. J., & Bilder, R. M. (1996) · PubMed · Cited by 211
Effects of clozapine on cognitive function in schizophrenia.
Lee, M. A., Thompson, P. A., & Meltzer, H. Y. (1994) · PubMed · Cited by 196
Faries, D., Ascher-Svanum, H., Zhu, B., Correll, C., & Kane, J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-26 · Cited by 184
Does cognitive function improve with quetiapine in comparison to haloperidol?
Velligan, D. I., Newcomer, J., Pultz, J., Csernansky, J., Hoff, A. L., Mahurin, R., & Miller, A. L. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00268-7 · Cited by 183
Purdon, S. E., MALLA, A. K., Labelle, A., & Lit, W. (2001) · PubMed · Cited by 177
Høyberg, O. J., Fensbo, C., Lingjærde, O., Sloth‐Nielsen, M., Salvesen, I., & Remvig, J. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03480.x · Cited by 176
Reichenberg, A., Weiser, M., Rapp, M. A., Rabinowitz, J., Caspi, A., Schmeidler, J., Knobler, H. Y., Lubin, G., Nahon, D., Harvey, P. D., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.12.1297 · Cited by 168
Harvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1888 · Cited by 161
Harvey, P. D., Green, M. F., McGurk, S. R., & Meltzer, H. Y. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1342-5 · Cited by 156
Perlis, R. H., Purcell, S., D, M. F. M., Fagerness, J. A., Rush, A. J., Trivedi, M. H., & Smoller, J. W. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.689 · Cited by 150
Hoff, A. L. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00242-6 · Cited by 133
Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia
Chakos, M. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830040049009 · Cited by 132
Another view of therapy for cognition in schizophrenia
Carpenter, W. T., & Gold, J. M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01399-9 · Cited by 127
Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Rock, S. L., Woolson, S., Tohen, M. F., Tollefson, G. D., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.022 · Cited by 121
Self-citationLee, M., Jayathilake, K., & Meltzer, H. Y. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00145-5 · Cited by 120
Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study
Rossi, A., Mancini, F., Stratta, P., et al. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb00371.x · Cited by 120
Haro, J. M., Edgell, E. T., Jones, P. B., Alonso, J., Gavart, S., Gregor, K. J., Wright, P., Knapp, M. R. J., & on behalf of the SOHO Study Group (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00064.x · Cited by 115
Keefe, R. S. E., Mohs, R. C., Bilder, R. M., Harvey, P. D., Green, M. F., Meltzer, H. Y., Gold, J. M., & Sano, M. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006990 · Cited by 111
Self-citationSwartz, M. S., Perkins, D. O., Stroup, T. S., McEvoy, J. P., Nieri, J., & Haak, D. C. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006989 · Cited by 109
Risperidone versus Haloperidol on Secondary Memory: Can Newer Medications Aid Learning?
Kern, R. S., Green, M. F., Marshall, B. D., Wirshing, W. C., Wirshing, D. A., McGurk, S. R., Marder, S. R., & Mintz, J. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033375 · Cited by 93
Harvey, P. D., Meltzer, H. Y., Simpson, G. M., Potkin, S. G., Loebel, A. D., SIU, C. O., & Romano, S. J. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.07.009 · Cited by 91
The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia
McGurk, S. R., Carter, C., GOLDMAN, R. S., Green, M. F., Marder, S. R., Xie, H., Schooler, N. R., & Kane, J. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.1013 · Cited by 89
Kern, R. S., Green, M. F., Marshall, B. D., Wirshing, W. C., Wirshing, D. A., McGurk, S. R., Marder, S. R., & Mintz, J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00088-2 · Cited by 88
Harvey, P. D., SIU, C. O., & Romano, S. J. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1652-2 · Cited by 83
Wagner, M., Quednow, B. B., Westheide, J., Schlaepfer, T. E., Maier, W., & Kühn, K.-U. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300626 · Cited by 80
Velligan, D. I., Prihoda, T. J., Sui, D., Ritch, J., Maples, N. J., & Miller, A. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0505 · Cited by 78
Harvey, P. D., Napolitano, J. A., Mao, L., & Gharabawi, G. M. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.929 · Cited by 75
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia
Sharma, T., Hughes, C., Soni, W., & Kumari, V. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1506-y · Cited by 73
Clozapine Enhances Neurocognition and Clinical Symptomatology More Than Standard Neuroleptics
Potkin, S. G., Fleming, K., Jin, Y., & Gulasekaram, B. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00004 · Cited by 67
Practice-related improvement in information processing with novel antipsychotic treatment
Harvey, P. D., Moriarty, P. J., Serper, M. R., Schnur, E., & Lieber, D. G. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00033-5 · Cited by 64
Good, K. P., Kiss, I., Buiteman, C., Woodley, H., Rui, Q., Whitehorn, D., & Kopala, L. C. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.181.43.s45 · Cited by 60
Tracy, K., Adler, L. A., Rotrosen, J., Edson, R., & Lavori, P. W. (1997) · PubMed · Cited by 58
Short- and Long-Term Spatial Delayed Response Performance Across the Lifespan
Lyons-Warren, A. M., Lillie, R., & Hershey, T. G. (2004) · Developmental Neuropsychology · doi:10.1207/s15326942dn2603_1 · Cited by 56
Rosenheck, R. A. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.1.85 · Cited by 54
Neuropsychological change in schizophrenia after 6 weeks of clozapine
Purdon, S. E., Labelle, A., & Boulay, L. J. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00101-8 · Cited by 51
Cognitive effects of olanzapine treatment in schizophrenia.
McGurk, S. R., Lee, M. A., Jayathilake, K., & Meltzer, H. Y. (2004) · PubMed · Cited by 47
The effects of clozapine on cognitive functioning in treatment- resistant schizophrenic patients
Fujii, D. E. M., Ahmed, I., Jokumsen, M., & Compton, J. (1997) · Journal of Neuropsychiatry · doi:10.1176/jnp.9.2.240 · Cited by 47
Effects of Clozapine on Psychiatric Symptoms, Cognition, and Functional Outcome in Schizophrenia
Manschreck, T. C., Redmond, D. A., Candela, S. F., & Maher, B. A. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.4.481 · Cited by 44
Davis, S. M., Koch, G. G., DAVIS, C. E., & LaVange, L. M. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006993 · Cited by 44
Effects of quetiapine on cognitive functions in schizophrenia
Akdede, B. B., Alptekın, K., Kitiş, A., Arkar, H., & Akvardar, Y. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.005 · Cited by 41
Vaïva, G., Thomas, P., Llorca, P., Dupont, S., Cottencin, O., Devos, P., Mazas, O., Rascle, C., Steinling, M., & Goudemand, M. (2002) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(02)00031-8 · Cited by 40
Stip, É., Remington, G. J., Dursun, S. M., Reiss, J. P., Rotstein, E., MacEwan, G. W., Chokka, P. R., Jones, B., & Dickson, R. A. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085414.08426.8f · Cited by 31
Effects of Clozapine for Non-Treatment-Resistant Patients With Schizophrenia
Galletly, C. A., Clark, C. R., McFARLANE, A. C., & Weber, D. L. (1999) · Psychiatric Services · doi:10.1176/ps.50.1.101 · Cited by 20
Rosenheck, R. A., Doyle, J., LESLIE, D. L., & FONTANA, A. F. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006994 · Cited by 19
Chua, L., Chong, S. A., Pang, E., Ng, V. P., & Chan, Y. H. (2001) · PubMed · Cited by 12
Fleming, K., Thyrum, P. T., Yeh, C., Vargo, D. L., & Potkin, S. G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00011 · Cited by 12
Cited by
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
The Diagnosis of Mental Disorders: The Problem of Reification
Hyman, S. E. (2010) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.3.022806.091532 · Cited by 1,052
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,027
Schizophrenia Is a Cognitive Illness: Time for a Change in Focus
Kahn, R. S., & Keefe, R. S. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.155 · Cited by 825
Self-citation
Metadata
- Authors
- Keefe, R. S. E.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2007-06-01
- Volume
- 64
- Issue
- 6
- Pages
- 633
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2170792659
- Cited by
- 1,065
- References
- 83
- FWCI
- 45.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.